-
公开(公告)号：US20120142759A1
公开(公告)日：2012-06-07
申请号：US12598453
申请日：2007-10-19
申请人： Peter L. Sazani , Maria Graziewicz , Ryszard Kole
发明人： Peter L. Sazani , Maria Graziewicz , Ryszard Kole
IPC分类号： A61K31/7088 , A61P29/00 , C12N5/02 , C07H21/04
CPC分类号： C07K14/7151 , A61K48/00 , C07H21/04 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/346 , C12N2320/33 , C12N2310/3521
摘要： The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has thereputic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.
摘要翻译： 本发明涉及剪接切换寡核苷酸或剪接切换寡聚体（SSO）。 根据本发明的优选SSO靶向TNFR1（TNFRSF1A）或TNFR2（TNFRSF1A）前mRNA的外显子7，通常导致在部分或全部外显子7中包含缺失的TNFR变体的产生。 发现针对外显子7的SSOs导致TNFR的可溶形式，其具有治疗炎性疾病的有益效果。 SSO的特点是它们基本上无能力或不能招募RNaseH。
-
公开(公告)号：US20070249538A1
公开(公告)日：2007-10-25
申请号：US11799117
申请日：2007-05-01
申请人： Peter Sazani , Maria Graziewicz , Ryszard Kole
发明人： Peter Sazani , Maria Graziewicz , Ryszard Kole
IPC分类号： A61K38/16 , A61K31/7052 , A61P29/00 , C07H21/00 , C07K14/00 , C12N1/00 , C12N15/00 , C12N15/63 , C12N5/00 , C12P21/00
CPC分类号： C07K14/70578 , A61K38/00 , A61K48/00 , C07H21/04 , C07K14/7151 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/346 , C12N2320/33 , Y02A50/463 , C12N2310/3521
摘要： The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
摘要翻译： 本发明涉及肿瘤坏死因子（TNF）拮抗剂和衍生自肿瘤坏死因子受体（TNFR）的相应核酸及其在治疗炎性疾病中的用途。 这些蛋白质是可溶性分泌的诱饵受体，其结合TNF并阻止TNF向信号传导。 特别地，蛋白质是缺乏外显子7并且可以结合TNF并且可以作为TNF拮抗剂的哺乳动物TNFR。
-
公开(公告)号：US07785834B2
公开(公告)日：2010-08-31
申请号：US11799117
申请日：2007-05-01
申请人： Peter L. Sazani , Maria Graziewicz , Ryszard Kole , Henrik Ørum
发明人： Peter L. Sazani , Maria Graziewicz , Ryszard Kole , Henrik Ørum
CPC分类号： C07K14/70578 , A61K38/00 , A61K48/00 , C07H21/04 , C07K14/7151 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/346 , C12N2320/33 , Y02A50/463 , C12N2310/3521
摘要： The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
摘要翻译： 本发明涉及肿瘤坏死因子（TNF）拮抗剂和衍生自肿瘤坏死因子受体（TNFR）的相应核酸及其在治疗炎性疾病中的用途。 这些蛋白质是可溶性分泌的诱饵受体，其结合TNF并阻止TNF向信号传导。 特别地，蛋白质是缺乏外显子7并且可以结合TNF并且可以作为TNF拮抗剂的哺乳动物TNFR。
-
-
搜索结果
3 条记录 (耗时 0.013 秒)
